References
- Rajagopal PS, Nipp RD, Selvaggi KJ. Chemotherapy for advanced cancers. Ann Palliat Med 2014;3:203-28.
- Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ 2014;348:g1219. https://doi.org/10.1136/bmj.g1219
- Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003;138:639-43. https://doi.org/10.7326/0003-4819-138-8-200304150-00011
- Barbera L, Paszat L, Chartier C. Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care 2006;22:12-7.
- Yun YH, Kwak M, Park SM, Kim S, Choi JS, Lim HY, et al. Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 2007;72:164-71. https://doi.org/10.1159/000112802
- Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, et al. Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol 2008;38:381-6. https://doi.org/10.1093/jjco/hyn031
- Kao S, Shafiq J, Vardy J, Adams D. Use of chemotherapy at end of life in oncology patients. Ann Oncol 2009;20:1555-9. https://doi.org/10.1093/annonc/mdp027
- Frigeri M, De Dosso S, Castillo-Fernandez O, Feuerlein K, Neuenschwander H, Saletti P. Chemotherapy in patients with advanced pancreatic cancer: too close to death? Support Care Cancer 2013;21:157-63. https://doi.org/10.1007/s00520-012-1505-9
- Hong JH, Rho SY, Hong YS. Trends in the aggressiveness of end-of-life care for advanced stomach cancer patients. Cancer Res Treat 2013;45:270-5. https://doi.org/10.4143/crt.2013.45.4.270
- Sezgin Goksu S, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, et al. Use of chemotherapy at the end of life in Turkey. BMC Palliat Med 2014;13:51. https://doi.org/10.1186/1472-684X-13-51
- Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012;30: 1715-24. https://doi.org/10.1200/JCO.2012.42.8375
- Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29:1587-91. https://doi.org/10.1200/JCO.2010.31.9897
- Barnato AE, Herndon MB, Anthony DL, Gallagher PM, Skinner JS, Bynum JP, et al. Are regional variations in end-of-life care intensity explained by patient preferences?: A Study of the US Medicare Population. Med Care 2007;45:386-93. https://doi.org/10.1097/01.mlr.0000255248.79308.41
- Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? a review of the perspective of those facing death from cancer. J Clin Oncol 2006;24: 3490-6. https://doi.org/10.1200/JCO.2005.03.6236
- Hui D, Karuturi MS, Tanco KC, Kwon JH, Kim SH, Zhang T, et al. Targeted agent use in cancer patients at the end of life. J Pain Symptom Manage 2013;46:1-8. https://doi.org/10.1016/j.jpainsymman.2012.07.007
- Choi Y, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. Cancer treatment near the end-of-life becomes more aggressive: changes in trend during 10 Years at a single Institute. Cancer Res Treat 2015;47:555-63. https://doi.org/10.4143/crt.2014.200
- Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-73. https://doi.org/10.1093/annonc/mdv249
- Huang HL, Chiu TY, Lee LT, Yao CA, Chen CY, Hu WY. Family experience with difficult decisions in end-of-life care. Psychooncol 2012;21:785-91. https://doi.org/10.1002/pon.3107
- Wentlandt K, Burman D, Swami N, Hales S, Rydall A, Rodin G, et al. Preparation for the end of life in patients with advanced cancer and association with communication with professional caregivers. Psychooncology 2012;21:868-76. https://doi.org/10.1002/pon.1995
- Chunlestskul K, Carlson LE, Koopmans JP, Angen M. Lived experiences of Canadian women with metastatic breast cancer in preparation for their death: a qualitative study. Part II-enabling and inhibiting factors; the paradox of death preparation. J Palliat Care 2008;24:16-25.
- Johnston SC, Pfeifer MP, McNutt R. The discussion about advance directives. Patient and physician opinions regarding when and how it should be conducted. End of Life Study Group. Arch Intern Med 1995;155:1025-30. https://doi.org/10.1001/archinte.1995.00430100047005
- Baek SK, Kim SY, Heo DS, Yun YH, Lee MK. Effect of advanced cancer patients' awareness of disease status on treatment decisional conflicts and satisfaction during palliative chemotherapy: a Korean prospective cohort study. Support Care Cancer 2012;20:1309-16. https://doi.org/10.1007/s00520-011-1218-5
- Kim DY. The impact of implementation to cancer patient's medical payment rate decreasing system on the health expenditure and m medical utilization of elderly colon cancer patients [master's thesis]. Seoul: Yonsei Univ.; 2008. Korean.
- Zdenkowski N, Cavenagh J, Ku YC, Bisquera A, Bonaventura A. Administration of chemotherapy with palliative intent in the last 30 days of life: the balance between palliation and chemotherapy. Intern Med 2013;43:1191-8. https://doi.org/10.1111/imj.12245
Cited by
- The Disease Burden of Lung Cancer Attributable to Residential Radon Exposure in Korean Homes vol.33, pp.29, 2018, https://doi.org/10.3346/jkms.2018.33.e223